•Initiation by Tertiary Epilepsy Specialist only.
•For adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with severe refractory epilepsy warranting tertiary specialist input for patients who have tried three or more AEDs. The patient has used levetiracetam and has documentation of intolerance and patient is using a third line agent (perampanel, zonisamide, lacosamide, eslicarbazepine) which would be replaced by brivaracetam

Supported by an ESCA

In line with NICE

In line with NICE

Severe myoclonic epilepsy of infancy (Dravet syndrome)
APC supports use in Adults: for continuation of therapy started in childhood. (Note Off Label use in adults)

MHRA Advice
Care should be taken when switching between oral formulations. The need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history

Prescribe in accordance with NICE TA232
Prescribing restrictions imposed by the MHRA July 2013. Monitor for ocular side effects and complete yellow cards as appropriate.
To be discontinued from June 2017 (see link below)